Compare RENX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | MTNB |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.2M |
| IPO Year | N/A | 2014 |
| Metric | RENX | MTNB |
|---|---|---|
| Price | $2.05 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 124.8K | 18.9K |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $0.48 |
| 52 Week High | $3.48 | $3.09 |
| Indicator | RENX | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 60.52 |
| Support Level | $1.62 | $0.57 |
| Resistance Level | $2.21 | $0.78 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.77 | 48.42 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.